Kissei Pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd. Fundamental Analysis
Kissei Pharmaceutical Co., Ltd. (4547.T) shows moderate financial fundamentals with a PE ratio of 12.05, profit margin of 14.14%, and ROE of 6.37%. The company generates $97.5B in annual revenue with strong year-over-year growth of 10.28%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 57.2/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 4547.T's fundamental strength across five key dimensions:
Efficiency Score
Weak4547.T struggles to generate sufficient returns from assets.
Valuation Score
Excellent4547.T trades at attractive valuation levels.
Growth Score
Excellent4547.T delivers strong and consistent growth momentum.
Financial Health Score
Excellent4547.T maintains a strong and stable balance sheet.
Profitability Score
Weak4547.T struggles to sustain strong margins.
Key Financial Metrics
Is 4547.T Expensive or Cheap?
P/E Ratio
4547.T trades at 12.05 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 4547.T's PEG of 0.58 indicates potential undervaluation.
Price to Book
The market values Kissei Pharmaceutical Co., Ltd. at 0.72 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 10.21 times EBITDA. This signals the market has high growth expectations.
How Well Does 4547.T Make Money?
Net Profit Margin
For every $100 in sales, Kissei Pharmaceutical Co., Ltd. keeps $14.14 as profit after all expenses.
Operating Margin
Core operations generate -3.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $6.37 in profit for every $100 of shareholder equity.
ROA
Kissei Pharmaceutical Co., Ltd. generates $5.01 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Kissei Pharmaceutical Co., Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Kissei Pharmaceutical Co., Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
4547.T converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
12.05
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.58
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.72
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.71
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.005
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.30
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.06
vs 25 benchmark
ROA
Return on assets percentage
0.05
vs 25 benchmark
ROCE
Return on capital employed
-0.01
vs 25 benchmark
How 4547.T Stacks Against Its Sector Peers
| Metric | 4547.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 12.05 | 29.20 | Better (Cheaper) |
| ROE | 6.37% | 684.00% | Weak |
| Net Margin | 14.14% | -52872.00% (disorted) | Strong |
| Debt/Equity | 0.01 | 0.38 | Strong (Low Leverage) |
| Current Ratio | 5.30 | 4.00 | Strong Liquidity |
| ROA | 5.01% | -19764.00% (disorted) | Weak |
4547.T outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Kissei Pharmaceutical Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
58.40%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
192.73%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
34.41%
Industry Style: Defensive, Growth, Innovation
High Growth